Source Docwire News, May 2025
Early-stage (IA, IB, IIA) cutaneous melanoma (CM) is typically managed with wide local excision (WLE). Despite this, some patients experience relapse, suggesting the presence of preoperative micrometastases. Identifying patients at high risk for relapse could inform the use of adjuvant therapies. To date, no studies have compared coding mutations among patients who have stage IA-IIA CM with and without relapse.
Researchers assess clinical and pathologic factors to support the use of whole-exome sequencing (WES) in identifying mutations associated with relapse. The results will be presented at American Society of Clinical Oncology 2025 Annual Meeting from May 30 to June 3, 2025.